Archivel Farma is pleased to share the progress achieved through an R&D project focused on the development and production of bacteriophages targeting Staphylococcus aureus and Klebsiella pneumoniae, two clinically relevant…
Archivel Farma announces that it has received the renewal of its GMP certification for manufacturing, confirming compliance with the requirements of the new Annex 1 to produce sterile and freeze-dried…
Archivel Farma is delighted to anounce the outcome of RUTIVAC study in Bladder Cancer. The RUTI® vaccine, developed and produced in-house by Archivel Farma, was tested in a phase I…
We were pleased to welcome Natalya Serbina, Senior Director at TB Alliance, to Archivel as part of our ongoing collaboration within the international Host Directed Therapy in Tuberculosis project. This…
“Yes! We Can End TB: Commit, Invest, Deliver” TB continues to cause immense human suffering and severe health, social, and economic consequences across the world. Every year, 10 million people…
Today is #WorldTBDay, a day to raise awareness about the devastating impact of #tuberculosis – one of the world’s oldest and deadliest diseases. #YesWeCanEndTB. #Archivelfarma is aligned with WHO goals…
The STRITUVAD (In Silico TRIals for TUberculosis VAccine Development) project has been completed. It has been a great honour for Archivel to be part of this project co-funded by the…
A new clinical trial, CONSTAN-ARG, will test the effectiveness of the #RUTI® vaccine to shorten treatment in #TB patients. #Archivel Farma has designed and set up a phase IIb clinical study called CONSTAN-ARG to…
Innovative Products
Fogars de Tordera, 61
Pol. Ind. Bonavista
08916 Badalona
T. +34 93 497 24 56
archivel@archivelfarma.com